Analysis of drug development risks for metabolic dysfunction-associated steatotic liver disease from a sustainable accounting perspective

Cost Effectiveness and Resource Allocation · Published 2026-08-04 · DOI 10.1186/s12962-026-00804-2

Free full text

Authors (2)

Xiyan Liu, Mohammed Mirza

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Liu, X., Mirza, M. (2026). Analysis of drug development risks for metabolic dysfunction-associated steatotic liver disease from a sustainable accounting perspective. Cost Effectiveness and Resource Allocation. https://doi.org/10.1186/s12962-026-00804-2

Related articles

• Exploring trends of cost-effectiveness thresholds in South Korea: systematic review of pharmacoeconomic evaluations since introduction of the positive list system · Cost Effectiveness and Resource Allocation · 2026 · Same journal
• Economic evaluation of PET-CT in staging and response assessment of patients with diffuse large B-cell lymphoma (DLBCL) in Thailand: a cost-utility analysis · Cost Effectiveness and Resource Allocation · 2026 · Same journal
• How accurate should a precision medical test be to meet cost-effectiveness · Cost Effectiveness and Resource Allocation · 2026 · Same journal
• Financial strain beyond coverage: assessing out-of-pocket costs for dialysis care in chronic kidney disease at a tertiary care centre in Central India · Cost Effectiveness and Resource Allocation · 2026 · Same journal
• Influence of clinical benefit and cost-effectiveness on reimbursement decisions for lung cancer drugs in Spain · Cost Effectiveness and Resource Allocation · 2026 · Same journal
• Ghana’s Diagnosis Related Grouping (G-DRG) tariffs versus hospital charges: implications for inpatient care financing at a secondary hospital in Ghana · Cost Effectiveness and Resource Allocation · 2026 · Same journal
• The impact of hospital bed supply on medical insurance expenditure in China (2011–2024): evidence on Roemer’s Law and threshold effects · Cost Effectiveness and Resource Allocation · 2026 · Same journal
• Economic burden of knee replacement, a case of Bushehr, Iran in 2023–2024 · Cost Effectiveness and Resource Allocation · 2026 · Same journal
• Costs of venovenous extracorporeal membrane oxygenation (VV-ECMO) and its potential contribution to quality-adjusted life years: a mixed-methods study protocol · Cost Effectiveness and Resource Allocation · 2026 · Same journal
• Extended cost-effectiveness analysis in global health systems: a scoping review of geographic gaps and research trends · Cost Effectiveness and Resource Allocation · 2026 · Same journal